GlobeNewswire

Lubrizol Acquires Bavaria Medizin Technologie GmbH

Share

The acquisition expands Lubrizol’s medical device design, development and manufacturing capabilities and adds expertise in drug-coated balloons and innovative catheter-based products

CLEVELAND, July 15, 2019 (GLOBE NEWSWIRE) -- The Lubrizol Corporation announces the acquisition of Bavaria Medizin Technologie GmbH (BMT), an innovative designer and manufacturer of both intravascular (coronary, peripheral, and cranial) and nonvascular devices, including drug-coated balloons, by its German subsidiary Lubrizol Deutschland GmbH from its current majority shareholder Custos Vermögensverwaltungs GmbH as well as from the minority shareholders.

This acquisition builds upon Lubrizol’s expertise in precision thermoplastic extrusion and product development, establishing Lubrizol as a true end-to-end partner to the global medical device and pharmaceutical industries.

With over 100 employees, BMT is headquartered near Munich, Germany and operates a manufacturing facility in Sibiu, Romania. A pioneer in catheter-based technologies, BMT developed the first commercial drug-coated balloon, the Paccocath™ catheter. Today, BMT holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services. Additionally, BMT offers private label manufacturing of proprietary catheters and balloons along with original equipment manufacturing (OEM) services, which include the manufacturing of subassemblies and components, sterilization, packaging and labeling, stent crimping, and logistics management.

The acquisition of BMT expands Lubrizol’s product design, development, and manufacturing expertise and provides access to proprietary catheter and balloon technologies. BMT’s experience and reputation in the drug-coated balloon (DCB) space aligns well with Lubrizol’s pharmaceutical CDMO business and positions Lubrizol as the ideal partner for developing next generation DCBs.

“Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space,” said Uwe Winzen, general manager of the Health business of Lubrizol Life Science. “Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services.”

About Lubrizol Life Science – Health
The Health business team at Lubrizol Life Science partners with customers to speed their innovative medical devices and differentiated pharmaceutical products to market. Our dedicated team provides best-in-class polymers and excipients, along with state-of-the-art product design, development, and manufacturing services, with the ultimate goal of creating solutions that improve patient outcomes. For more information about the Health business of Lubrizol Life Science, visit www.Lubrizol.com/Life-Sciences.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers’ products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers’ success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2018 were $6.8 billion. For more information, visit Lubrizol.com.

Media Contact
Nicholas DiFranco
(216) 447-6728
Nicholas.DiFranco@lubrizol.com Website: www.lubrizol.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/249896f6-1da6-4a32-9091-c7e3d5c33bd0

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ENR Russia Invest SA announces a new private equity investment and end third quarter 2019 net asset value per share23.10.2019 19:15:00 CESTPress release

Press Release Geneva, 23 October 2019 ENR RUSSIA INVEST SA ANNOUNCES A NEW PRIVATE EQUITY INVESTMENT AND END THIRD QUARTER 2019 NET ASSET VALUE PER SHARE New private equity investment ENR Russia Invest SA, via a wholly owned subsidiary (“ENR”), acquired a 50% interest in a 27.4 hectare greenhouse and engineering facility for flower growing in the Kaluga Oblast in Russia (“Flower Growing Facility”). ENR teamed-up with a Russia based investment group, who owns the remaining 50% interest (collectively referred to as the “Investors”). The purchase price and initial investment for capital and operational expenses is RUB 742 million (approximately CHF 11.5 million). ENR’s 50% contribution is RUB 371 million (approximately CHF 5.75 million). Together with further investments (see below), it is anticipated that the Investors could ultimately invest a total of about CHF 20 million (or less if low interest rate Russian bank funding can be obtained under Russian agricultural incentive programs).

Press Release: Giuseppe Pasceri appointed as General Manager for Adevinta in Italy23.10.2019 17:00:00 CESTPress release

Italy, 23 october 2019: Adevinta, a global online classifieds company with generalist, real estate, cars, jobs and other internet marketplaces in 16 countries, today announces that Giuseppe Pasceri will succeed Melany Libraro as the new General Manager for Adevinta in Italy, overseeing Subito and InfoJobs. Giuseppe joined Adevinta Italy in 2018 from the Italian Government Digital Team, bringing extensive experience in digital transformation and user-centered businesses. He most recently served as Chief Product Officer and Chief Technology Officer for Adevinta Italy. Giuseppe has over 25 years of experience in digital businesses, having worked for companies such as Yahoo!, eBay, RCS, Jobrapido and the Italian Government Digital Service. In his new role, Giuseppe will oversee all aspects of Subito and InfoJobs’ strategy and execution, with the goal to increase Adevinta’s leadership position in Italy and improve our users experience. “Giuseppe brings a thorough understanding of our users

Articles of Association, Seluxit A/S23.10.2019 15:32:00 CESTPress release

Articles of Association, Seluxit A/S Company Announcement No. 15 Aalborg, 23. October 2019 Articles of Association, Seluxit A/S. Following the completion of the registration with the Danish Commerce and Companies Agency (Erhvervsstyrelsen), attached you find the updated articles of association containing the changes which were decided at Seluxit A / S 'annual general meeting on October 22, 2019 For further information, please contact CEO Daniel Lux. You can subscribe to our investor newsletter on https://www.seluxit.com/investors and get company announcements directly in your mail box. You can also follow news from Seluxit on Homepage: https://www.seluxit.com/blog LinkedIn: https://www.linkedin.com/company/seluxit Facebook: https://www.facebook.com/seluxit Seluxit A/S Hjulmagervej 32B 9000 Aalborg Denmark Tel.: +45 46 922 722 E-mail: investor@seluxit.com Web: www.seluxit.com CVR/VAT nr. 29388237 Certified Adviser Norden CEF ApS, V/ John Norden Kongevejen 365, 2840 Holte Denmark Tel.: +

Aker and REV Ocean Pledge USD 11 million to Technology Initiatives for a Healthy Ocean23.10.2019 15:15:00 CESTPress release

Oslo, 23 October 2019 – The Aker Group, REV Ocean and The Resource Group (TRG) today announced a joint pledge of USD 11 million to three initiatives dedicated to developing disruptive technology solutions for a healthy and productive ocean. “Throughout its 180-year history, the Aker group has been a driving force in the development of knowledge-based industry related to ocean resources. All our industrial activities are part of the ocean economy,” said Aker President and CEO Øyvind Eriksen. “Today, our ocean is at risk and changes are needed. I strongly believe that solutions for the ocean are developed more robustly and swiftly if businesses like Aker join forces with governments, NGOs and other stakeholders. A healthier ocean is a shared interest,” he said. The USD 11 million pledge will go towards three initiatives, covering costs for the next three years. The initiatives include the Centre for the Fourth Industrial Revolution (C4IR) in Norway, which will receive USD 6 million, the

AB Klaipėdos nafta (KN) will hold an Investor Conference Webinar to introduce unaudited financial results for the nine months of 201923.10.2019 14:33:00 CESTPress release

KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the October 30th of 2019 at 8.30 am (EET). The presentation will be held in English. The webinar will be hosted by Company’s management who will introduce the performance and unaudited financial results of KN for the nine months of 2019. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until October 28th to Justinas.Juknys@nasdaq.com How to join the webinar? To join the webinar, please register via following link: https://attendee.gotowebinar.com/register/2162981666275406850 You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can't be downloaded, a web browser which enables attending the w

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-4323.10.2019 13:30:00 CESTPress release

Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases TORONTO and CAMBRIDGE, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated antibody candidates targeting the neurotoxic form of TAR DNA-binding protein 43 (TDP-43), a protein found in all cells and implicated as a root cause in a spectrum of diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). New data generated by ProMIS’ unique drug discovery and development platform demonstrate that several antibody candidates show selectivity for toxic, misfolded intracellular aggregates of TDP-43 with no binding to normal TDP-43 located in the cell nucleus. ProMIS antibody candidates also show selective bi